Institutions / Baker Bros. Advisors LP / Holdings
Back to Baker Bros. Advisors LP

Baker Bros. Advisors LP

All holdings · as of Mar 31, 2026

84 positions

CompanyClassValueShares% of portfolio
INCYTE CORP—$2.89B30,744,41216.6%
BeOne Medicines Ltd.ONCADR$2.61B8,799,05315.0%
INSMED INC—$1.21B7,421,1117.0%
MADRIGAL PHARMACEUTICALS, INC.—$1.12B2,141,7016.4%
ACADIA Pharmaceuticals Inc—$954.88M42,896,6905.5%
Revolution Medicines, Inc.—$929.26M9,555,3575.3%
Celcuity Inc.CELCCommon Stock$903.51M7,915,7925.2%
Kodiak Sciences Inc.KODCommon Stock$759.32M19,919,1864.4%
Kymera Therapeutics, Inc.—$721.06M8,657,2424.1%
Summit Therapeutics Inc.SMMTCommon Stock$689.97M36,391,0634.0%
Praxis Precision Medicines, Inc.—$564.86M1,753,1983.2%
RHYTHM PHARMACEUTICALS, INC.—$487.42M5,604,4832.8%
Alkermes plc.—$354.03M10,012,2672.0%
GRAIL, Inc.—$208.20M4,028,6141.2%
Edgewise Therapeutics, Inc.—$207.14M6,575,9401.2%
IONIS PHARMACEUTICALS INC—$153.76M2,047,7270.9%
Kiniksa Pharmaceuticals International, plc—$136.08M2,826,2460.8%
Immunovant, Inc.IMVTCommon Stock$135.57M5,457,8810.8%
Roivant Sciences Ltd.—$134.84M4,867,7230.8%
IDEAYA BIOSCIENCES, INC.—$131.50M3,946,5150.8%
ARROWHEAD PHARMACEUTICALS, INC.—$124.95M1,992,7830.7%
Stoke Therapeutics, Inc.—$108.64M3,336,6970.6%
Immatics N.V.—$107.42M10,916,6930.6%
AbCellera Biologics Inc.—$105.66M30,275,9380.6%
Abivax S.A.—$97.52M875,7960.6%
Crinetics Pharmaceuticals, Inc.—$85.41M2,351,4650.5%
Replimune Group, Inc.—$84.50M11,045,3360.5%
Celcuity Inc.—$74.87M30,750,0000.4%
Nurix Therapeutics, Inc.—$72.21M4,658,5560.4%
Denali Therapeutics Inc.—$71.65M3,731,6950.4%
Dianthus Therapeutics, Inc.—$71.51M852,1640.4%
Monte Rosa Therapeutics, Inc.—$71.49M4,345,7360.4%
Structure Therapeutics Inc.GPCRADR$69.05M1,432,5290.4%
Entrada Therapeutics, Inc.TRDACommon Stock$64.02M5,072,7300.4%
Bicycle Therapeutics plcBCYCADR$50.51M10,885,3570.3%
SPYRE THERAPEUTICS, INC.—$50.44M1,000,0000.3%
Rapport Therapeutics, Inc.RAPPCommon Stock$48.41M1,547,0900.3%
ALUMIS INC.ALMSCommon Stock$44.34M2,012,5000.3%
Mirum Pharmaceuticals, Inc.—$41.20M445,9750.2%
Viridian Therapeutics, Inc.—$38.57M1,971,6780.2%
Enliven Therapeutics, Inc.ELVNCommon Stock$35.48M905,1910.2%
Prelude Therapeutics Incorporated—$34.62M10,123,8240.2%
DBV TECHNOLOGIES S.A.DBVTADR$30.53M1,461,4250.2%
Design Therapeutics, Inc.DSGNCommon Stock$27.51M2,585,9780.2%
Centessa Pharmaceuticals plc—$26.64M670,7510.2%
CytomX Therapeutics, Inc.—$23.39M4,975,8260.1%
JADE BIOSCIENCES, INC.—$23.06M1,641,1370.1%
Disc Medicine, Inc.IRONCommon Stock$22.36M349,6570.1%
IMMUNOCORE HOLDINGS PLC-ADRIMCRADR$22.14M734,3970.1%
Xenon Pharmaceuticals Inc.—$21.53M370,2080.1%
← PrevPage 1 of 2Next →